When lawyers for users of the diet drug fen-phen agreed to settle a federal class-action suit against the manufacturer last month, it looked as if the resolution was going to leave most parties satisfied. People who used the drug before it was pulled off the market on suspicion of causing heart malfunctions would be eligible for a free round of diagnostic tests and possible payment of up to almost $1.5 million. American Home Products’ stock price shot up once the threat of suits had been diffused, even though the settlement could cost the drug manufacturer up to $4.85 billion, including $449 million in plaintiffs’ attorneys’ fees.

But in the week of negotiations preceding the Oct. 7 memorandum of understanding between lead counsel and AHP, dissenters emerged from the ranks of plaintiffs’ counsel.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]